• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $NEOG

    Neogen Corporation

    Subscribe to $NEOG
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.

    IPO Year: 1989

    Exchange: NASDAQ

    Website: neogen.com

    Recent Analyst Ratings for Neogen Corporation

    DatePrice TargetRatingAnalyst
    12/19/2024$15.00Buy
    Guggenheim
    6/16/2023$22.00Overweight
    Wells Fargo
    11/22/2022Mkt Perform → Outperform
    William Blair
    7/12/2022$25.00Neutral
    Piper Sandler
    See more ratings

    Neogen Corporation SEC Filings

    See more
    • Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NEOGEN CORP (0000711377) (Filer)

      4/22/25 4:45:23 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Neogen Corporation

      10-Q - NEOGEN CORP (0000711377) (Filer)

      4/9/25 4:04:19 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - NEOGEN CORP (0000711377) (Filer)

      4/9/25 7:06:54 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NEOGEN CORP (0000711377) (Filer)

      4/9/25 7:00:53 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - NEOGEN CORP (0000711377) (Filer)

      4/7/25 12:36:52 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Neogen Corporation

      SCHEDULE 13G/A - NEOGEN CORP (0000711377) (Subject)

      4/7/25 11:51:49 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Neogen Corporation

      10-Q - NEOGEN CORP (0000711377) (Filer)

      1/15/25 3:53:14 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form NT 10-Q filed by Neogen Corporation

      NT 10-Q - NEOGEN CORP (0000711377) (Filer)

      1/10/25 4:03:15 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NEOGEN CORP (0000711377) (Filer)

      1/10/25 7:00:46 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - NEOGEN CORP (0000711377) (Filer)

      1/7/25 4:03:29 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    Neogen Corporation Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Woteki Catherine E bought $29,831 worth of shares (5,770 units at $5.17), increasing direct ownership by 77% to 13,244 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/25/25 4:32:35 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Borel James C bought $149,700 worth of shares (30,000 units at $4.99), increasing direct ownership by 50% to 90,474 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/25/25 2:45:19 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Boehm William T bought $26,175 worth of shares (5,000 units at $5.24), increasing direct ownership by 16% to 36,214 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/24/25 3:34:30 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Borel James C bought $171,290 worth of shares (35,000 units at $4.89), increasing direct ownership by 137% to 60,474 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/24/25 11:18:56 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Legal Officer Rocklin Amy M bought $62,375 worth of shares (12,500 units at $4.99), increasing direct ownership by 53% to 36,287 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/23/25 10:46:08 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Capello Jeffrey D bought $100,217 worth of shares (20,712 units at $4.84), increasing direct ownership by 350% to 26,629 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/22/25 3:37:21 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Tobin James P bought $47,268 worth of shares (10,000 units at $4.73), increasing direct ownership by 36% to 37,474 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/22/25 11:46:10 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Rodriguez Rafael A bought $34,306 worth of shares (7,474 units at $4.59), increasing direct ownership by 100% to 14,948 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/22/25 11:43:06 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Accounting Officer Moylan John Patrick bought $50,700 worth of shares (10,000 units at $5.07) (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/10/25 10:12:42 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CFO Naemura David H. bought $164,428 worth of shares (14,800 units at $11.11), increasing direct ownership by 32% to 61,434 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      1/16/25 3:28:46 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    Neogen Corporation Financials

    Live finance-specific insights

    See more
    • Neogen Announces Third-Quarter 2025 Results

      Revenue of $221.0 million. Net loss of $11.0 million; $(0.05) per diluted share. Adjusted Net Income1 of $20.9 million; $0.10 per diluted share. Adjusted EBITDA1 of $48.5 million. Updating full-year guidance. 1 Non-GAAP financial measures; see explanations and reconciliations that follow. Neogen Corporation (NASDAQ:NEOG) announced today the results of the third quarter ended February 28, 2025. "During the third quarter, we continued to make good progress on the integration and saw a solid underlying performance in our Food Safety segment," said John Adent, Neogen's President and Chief Executive Officer. "The quarter was impacted by lower sample collection revenue, but we made s

      4/9/25 7:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Third-Quarter Earnings Release Date

      LANSING, Mich., March 20, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) will issue its third-quarter earnings release before the opening of the market on Wednesday, April 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing:Toll-Free - North America: 1-800-549-8228International: (+1) 646-564-2877Conference ID: 63045 The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/inves

      3/20/25 4:15:00 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Preliminary¹ Second-Quarter 2025 Results

      Revenue of $231.3 million.Net loss of $456.3 million due to non-cash goodwill impairment; $(2.10) per diluted share.Adjusted Net Income2 of $24.4 million; $0.11 per diluted share.Adjusted EBITDA2 of $51.4 million.Updating full-year guidance.LANSING, Mich., Jan. 10, 2025 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG) announced today the preliminary results of the second quarter ended November 30, 2024. "The second quarter reflected steady progress, as we saw improvement across the business compared to the first quarter, with core revenue growth accelerating in both of our seg

      1/10/25 7:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen® Announces Change to Second-Quarter Earnings Release Date

      LANSING, Mich., Jan. 2, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) announced today that, due to U.S. equity markets being closed in observance of the National Day of Mourning for former U.S. President Jimmy Carter, it will now issue its second-quarter earnings release before the opening of the market on Friday, January 10, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing (800) 836-8184 (U.S.) or +1 (646)

      1/2/25 4:15:00 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen® Announces Second-Quarter Earnings Release Date

      LANSING, Mich., Dec. 19, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) will issue its second-quarter earnings release before the opening of the market on Thursday, January 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international) and requesting the Neogen Corporation Q2 FY25 Earnings Call. The live webcast can be accessed through Neogen's Investor Relation

      12/19/24 8:45:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces First-Quarter 2025 Results

      Revenue of $217.0 million.Net loss of $12.6 million; $(0.06) per diluted share.Adjusted Net Income of $14.4 million; $0.07 per diluted share.Adjusted EBITDA of $43.7 million.Maintaining full-year guidance.LANSING, Mich., Oct. 10, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG) announced today the results of the first quarter ended August 31, 2024. "During the first quarter, the focus of our teams shifted from managing through the initial complexity of exiting the transition service agreements from the 3M transaction to gaining market share," said John Adent, Neogen's Pre

      10/10/24 7:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen® Announces First-Quarter Earnings Release Date

      LANSING, Mich., Sept. 19, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) will issue its first-quarter earnings release before the opening of the market on Thursday, October 10, 2024. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international) and requesting the Neogen Corporation First Quarter 2025 Earnings Call. The live webcast can be accessed through Neogen's Inves

      9/19/24 8:45:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Fourth-Quarter 2024 Results

      Revenue of $236.8 million.Net loss of $5.4 million; $(0.02) per diluted share.Adjusted Net Income of $22.4 million; $0.10 per diluted share.Adjusted EBITDA of $53.0 million.LANSING, Mich., July 30, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG) announced today the results of the fourth quarter ended May 31, 2024. "After crossing multiple significant integration milestones in the third quarter related to the integration of the former 3M Food Safety business, progress continued on multiple fronts in the fourth quarter," said John Adent, Neogen's President and Chief Execut

      7/30/24 7:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Fourth-Quarter Earnings Release Date

      LANSING, Mich., July 11, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG) will issue its fourth-quarter earnings release before the opening of the market on Tuesday, July 30, 2024. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international) and requesting the Neogen Corporation Fourth Quarter 2024 Earnings Call. The live webcast can be accessed through Neogen's Investor

      7/11/24 4:30:00 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Third-Quarter 2024 Results

      Revenue of $228.8 million.Net loss of $(2.0) million; $(0.01) per diluted share.Adjusted Net Income of $26.4 million; $0.12 per diluted share.Adjusted EBITDA of $52.7 million.Updating full-year outlook.LANSING, Mich., April 9, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG) announced today the results of the third quarter ended February 29, 2024. "The third quarter saw us complete a number of milestone achievements related to the integration of the former 3M Food Safety business," said John Adent, Neogen's President and Chief Executive Officer. "We completed the relocati

      4/9/24 7:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    Neogen Corporation Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neogen Announces Sale of Cleaners & Disinfectants Business

      Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today it has entered into a definitive agreement to sell its global cleaners and disinfectants business to Kersia Group ("Kersia"), a global leader in biosecurity, disinfection and hygiene solutions, for $130 million in cash at closing plus contingent consideration tied to the future performance of the business. The transaction is expected to be accretive to margins and close in the first quarter of the Company's 2026 fiscal year, subject to regulatory approval and customary closing conditions. The net proceeds will be used to fully repay the $100 million drawn on the Company's revolving credit facili

      4/21/25 9:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen® Announces CEO Transition

      Board has Formed Search Committee and Engaged Leading Executive Search Firm Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced that John Adent, the Company's CEO and President, will be stepping down after an eight-year career at the Company. Mr. Adent will continue to serve in his existing roles until his successor has been appointed. Neogen's Board of Directors has formed a special committee, comprising Board Chair Jim Borel, Thierry Bernard and Jeff Capello, to direct the search for the Company's next CEO and has engaged a leading global executive search firm. The special committee will also support Mr. Adent and the leadership team as they

      4/9/25 7:01:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Third-Quarter 2025 Results

      Revenue of $221.0 million. Net loss of $11.0 million; $(0.05) per diluted share. Adjusted Net Income1 of $20.9 million; $0.10 per diluted share. Adjusted EBITDA1 of $48.5 million. Updating full-year guidance. 1 Non-GAAP financial measures; see explanations and reconciliations that follow. Neogen Corporation (NASDAQ:NEOG) announced today the results of the third quarter ended February 28, 2025. "During the third quarter, we continued to make good progress on the integration and saw a solid underlying performance in our Food Safety segment," said John Adent, Neogen's President and Chief Executive Officer. "The quarter was impacted by lower sample collection revenue, but we made s

      4/9/25 7:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen® Announces Refinancing of Term Loan and Revolving Credit Facility

      Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today the successful refinancing of the remaining $550 million principal of its original $650 million term loan, as well as its revolving credit facility, due in August 2027. The new $450 million term loan and $250 million revolving credit facility mature in April 2030, extending the previous maturity by over two and a half years. With an upsizing of the Company's revolving credit facility from $150 million to $250 million and an initial draw of $100 million, the refinancing represents a leverage-neutral transaction. Reflecting the Company's favorable credit profile and supportive banking partnershi

      4/7/25 9:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Third-Quarter Earnings Release Date

      LANSING, Mich., March 20, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) will issue its third-quarter earnings release before the opening of the market on Wednesday, April 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing:Toll-Free - North America: 1-800-549-8228International: (+1) 646-564-2877Conference ID: 63045 The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/inves

      3/20/25 4:15:00 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance
    • NLRB Withdraws Unfair Labor Practices Claim Against Neogen®

      LANSING, Mich., Feb. 18, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today the National Labor Relations Board (NLRB) has withdrawn its unfair labor practices claim against the Company. The claim was withdrawn following a mutual agreement, with no admission of wrongdoing by Neogen. In the coming weeks, Lansing warehouse shipping clerks and material handling employees will have the opportunity to vote in an election to determine whether they wish to unionize. "At Neogen, we are dedicated to fostering a supporti

      2/18/25 4:33:00 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen® Introduces Igenity® BCHF to Help Industry Mitigate Bovine Congestive Heart Failure Risk

      LINCOLN, Neb., Jan. 21, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food security solutions, announced today the launch of Igenity® BCHF to improve overall bovine heart health standards. Bovine Congestive Heart Failure (BCHF) stands as a significant threat to cattle health and productivity, and this genomic test provides a new opportunity for improved selection for heart health. Testing with Igenity BCHF assesses an animal's genetic predisposition for BCHF, scored on a 1-to-10 scale. Ranging from 1 (lowest risk) to 10 (highest risk of diseas

      1/21/25 8:45:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen® Launches New MDA2 Quantitative Salmonella Molecular Detection Assay

      LANSING, Mich., Jan. 16, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today the launch of the new Neogen Molecular Detection Assay 2 – Quantitative Salmonella (MDA2QSAL96). The Neogen MDA2QSAL96 kit integrates qualitative pathogen testing solutions and Quantitative Rapid Enrichment Dehydrated (QRED) media designed to enable controlled growth rates for quantitation, allowing poultry producers to verify the effectiveness of their interventions. This quantitative method delivers excellent consistency and sensitiv

      1/16/25 8:45:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen Announces Preliminary¹ Second-Quarter 2025 Results

      Revenue of $231.3 million.Net loss of $456.3 million due to non-cash goodwill impairment; $(2.10) per diluted share.Adjusted Net Income2 of $24.4 million; $0.11 per diluted share.Adjusted EBITDA2 of $51.4 million.Updating full-year guidance.LANSING, Mich., Jan. 10, 2025 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG) announced today the preliminary results of the second quarter ended November 30, 2024. "The second quarter reflected steady progress, as we saw improvement across the business compared to the first quarter, with core revenue growth accelerating in both of our seg

      1/10/25 7:00:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    Neogen Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Moylan John Patrick exercised 4,558 shares at a strike of $5.15 and covered exercise/tax liability with 1,603 shares, increasing direct ownership by 30% to 12,955 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      5/2/25 1:48:58 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CEO Adent John Edward exercised 2,112 shares at a strike of $5.16, increasing direct ownership by 0.78% to 271,276 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/29/25 1:39:59 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Operating Officer Jones Douglas Edward exercised 845 shares at a strike of $5.16 and covered exercise/tax liability with 291 shares, increasing direct ownership by 0.78% to 71,713 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/29/25 1:34:22 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Legal Officer Rocklin Amy M exercised 564 shares at a strike of $5.16, increasing direct ownership by 2% to 36,851 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/29/25 1:29:07 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Woteki Catherine E bought $29,831 worth of shares (5,770 units at $5.17), increasing direct ownership by 77% to 13,244 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/25/25 4:32:35 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Borel James C bought $149,700 worth of shares (30,000 units at $4.99), increasing direct ownership by 50% to 90,474 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/25/25 2:45:19 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Boehm William T bought $26,175 worth of shares (5,000 units at $5.24), increasing direct ownership by 16% to 36,214 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/24/25 3:34:30 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Borel James C bought $171,290 worth of shares (35,000 units at $4.89), increasing direct ownership by 137% to 60,474 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/24/25 11:18:56 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Legal Officer Rocklin Amy M bought $62,375 worth of shares (12,500 units at $4.99), increasing direct ownership by 53% to 36,287 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/23/25 10:46:08 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Capello Jeffrey D bought $100,217 worth of shares (20,712 units at $4.84), increasing direct ownership by 350% to 26,629 units (SEC Form 4)

      4 - NEOGEN CORP (0000711377) (Issuer)

      4/22/25 3:37:21 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    Neogen Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Neogen with a new price target

      Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00

      12/19/24 8:18:19 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Wells Fargo initiated coverage on Neogen with a new price target

      Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00

      6/16/23 7:34:39 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Neogen upgraded by William Blair

      William Blair upgraded Neogen from Mkt Perform to Outperform

      11/22/22 8:02:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Piper Sandler initiated coverage on Neogen with a new price target

      Piper Sandler initiated coverage of Neogen with a rating of Neutral and set a new price target of $25.00

      7/12/22 7:33:12 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    Neogen Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Neogen Corporation

      SC 13G - NEOGEN CORP (0000711377) (Subject)

      11/14/24 4:28:12 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Neogen Corporation

      SC 13G - NEOGEN CORP (0000711377) (Subject)

      11/14/24 11:16:20 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

      SC 13G/A - NEOGEN CORP (0000711377) (Subject)

      2/13/24 5:09:41 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

      SC 13G/A - NEOGEN CORP (0000711377) (Subject)

      2/9/24 11:58:12 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

      SC 13G/A - NEOGEN CORP (0000711377) (Subject)

      1/30/24 10:20:33 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

      SC 13G/A - NEOGEN CORP (0000711377) (Subject)

      2/14/23 10:47:37 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

      SC 13G/A - NEOGEN CORP (0000711377) (Subject)

      2/14/23 10:34:15 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

      SC 13G/A - NEOGEN CORP (0000711377) (Subject)

      2/9/23 11:27:43 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

      SC 13G/A - NEOGEN CORP (0000711377) (Subject)

      2/8/23 1:12:20 PM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

      SC 13G/A - NEOGEN CORP (0000711377) (Subject)

      10/11/22 9:52:04 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    Neogen Corporation Leadership Updates

    Live Leadership Updates

    See more
    • Neogen® Announces CEO Transition

      Board has Formed Search Committee and Engaged Leading Executive Search Firm Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced that John Adent, the Company's CEO and President, will be stepping down after an eight-year career at the Company. Mr. Adent will continue to serve in his existing roles until his successor has been appointed. Neogen's Board of Directors has formed a special committee, comprising Board Chair Jim Borel, Thierry Bernard and Jeff Capello, to direct the search for the Company's next CEO and has engaged a leading global executive search firm. The special committee will also support Mr. Adent and the leadership team as they

      4/9/25 7:01:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance
    • Neogen Announces the Appointment of New Board Member

      LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its

      10/1/24 8:45:00 AM ET
      $NEOG
      $QGEN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Neogen Announces the Appointment of Two New Board Members

      Board of Directors expanded in conjunction with the closing of the 3M Food Safety transaction LANSING, Mich., Sept. 12, 2022 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG), a leader in food and animal safety, announced today that it has appointed two new members to its Board of Directors: Jeffrey Capello and Aashima Gupta. The addition of Mr. Capello and Ms. Gupta was agreed by Neogen and 3M Company under the merger agreement for the 3M Food Safety transaction. "We are pleased to add these two experienced industry professionals to Neogen's Board of Directors," said Jim Borel, Neogen's Board Chair. "Their involvement in the global healthcare and biotechnology industries will be a significan

      9/12/22 8:45:00 AM ET
      $NEOG
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care